PHATHOM PHARMACEUTICALS INC (PHAT)
US71722W1071 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 682K | 52.667M 7,622.43% | 177.42M 236.87% | 389.44M 119.50% | 607.28M 55.94% | 772.16M 27.15% | 919.01M 19.02% | 1.031B 12.19% | 1.186B 15.03% | |||
| EBITDA YoY % growth | -134.56M -7.35% | -171.82M -27.69% | -166.737M 2.96% | -254.857M -52.85% | -199.916M 21.56% | -67.552M 66.21% | 89.241M 232.11% | 150.08M 68.17% | 244.58M 62.97% | 307.06M 25.55% | 332.71M 8.35% | |
| EBIT YoY % growth | -135.08M -7.49% | -172.44M -27.66% | -167.312M 2.97% | -283.774M -69.61% | -247.704M 12.71% | -125.158M 49.47% | 89.55M 171.55% | 210.56M 135.13% | 387.56M 84.06% | 483.79M 24.83% | 653.57M 35.09% | |
| Operating Margin | N/A | N/A | -24,532.55% | -538.81% | -139.61% | -32.14% | 14.75% | 27.27% | 42.17% | 46.92% | 55.11% | |
| EPS YoY % growth | -3.89 -0.78% | -5.05 -29.82% | -3.88 23.17% | -5.70 -46.90% | -4.47 21.51% | -2.18 51.21% | -0.34 84.58% | 1.17 446.97% | 2.55 118.34% | 3.21 26.00% | 3.45 7.30% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.27 8.76% | -1.26 11.17% | -1.10 29.60% | -0.96 27.11% | -0.78 38.87% |
| Revenue Q2Q % growth | 25.671M 3,664.08% | 28.585M 1,395.03% | 39.024M 432.82% | 50.146M 206.67% | 55.59M 116.55% |
| EBITDA Q2Q % growth | -55.977M 19.23% | -54.366M 22.04% | -48.144M 37.39% | -42.024M 40.13% | -33.66M 39.87% |
| EBIT Q2Q % growth | -67.063M 4.02% | -68.815M 1.63% | -60.337M 21.94% | -52.373M 26.02% | -46.002M 31.41% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -1.32 -73.68% | -1.52 | 0.20 | 13.44% |
| Q2 2024 Q2Q % growth | -1.56 -85.71% | -1.41 | -0.15 | -10.83% |
| Q1 2024 Q2Q % growth | -1.42 -59.55% | -1.34 | -0.08 | -6.34% |
| Q4 2023 Q2Q % growth | -1.39 -4.51% | -1.10 | -0.29 | -26.53% |
| Q3 2023 Q2Q % growth | -0.76 42.42% | -0.91 | 0.15 | 16.42% |
| Q2 2023 Q2Q % growth | -0.84 36.84% | -1.00 | 0.16 | 15.84% |
| Q1 2023 Q2Q % growth | -0.89 16.82% | -1.29 | 0.40 | 30.78% |
| Q4 2022 Q2Q % growth | -1.33 -40.00% | -1.38 | 0.05 | 3.53% |
| Q3 2022 Q2Q % growth | -1.32 -34.69% | -1.34 | 0.02 | 1.79% |
| Q2 2022 Q2Q % growth | -1.33 -33.00% | -1.05 | -0.28 | -26.59% |
| Q1 2022 Q2Q % growth | -1.07 -11.46% | -0.99 | -0.08 | -8.37% |
| Q4 2021 Q2Q % growth | -0.95 39.87% | -1.05 | 0.10 | 9.43% |
| Q3 2021 Q2Q % growth | -0.98 3.92% | -1.00 | 0.02 | 1.96% |
| Q2 2021 Q2Q % growth | -1.00 -56.25% | -1.09 | 0.09 | 8.23% |
| Q1 2021 Q2Q % growth | -0.96 -54.84% | -1.21 | 0.25 | 20.80% |
| Q4 2020 Q2Q % growth | -1.58 60.20% | -1.03 | -0.55 | -53.12% |
| Q3 2020 Q2Q % growth | -1.02 89.03% | -0.69 | -0.33 | -48.52% |
| Q2 2020 Q2Q % growth | -0.64 | -0.57 | -0.07 | -12.04% |
| Q1 2020 Q2Q % growth | -0.62 | -0.73 | 0.11 | 15.19% |
| Q4 2019 Q2Q % growth | -3.97 | -1.28 | -2.70 | -211.37% |
| Q3 2019 Q2Q % growth | -9.30 | -1.16 | -8.14 | -699.79% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 16.352M | 12.861M | 3.491M | 27.14% |
| Q2 2024 Q2Q % growth | 7.324M | 5.925M | 1.399M | 23.61% |
| Q1 2024 Q2Q % growth | 1.912M | 2.088M | -176K | -8.43% |
| Q4 2023 Q2Q % growth | 682K | 420.577K | 261.423K | 62.16% |
| Q3 2022 Q2Q % growth | 204K | -204K | -100.00% | |
| Q1 2022 Q2Q % growth | 215.22K | -215.22K | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | -12.69% | 4.77% | 5.8% |
| Revenue | 0% | 9.88% | 13.32% | 16.79% |